Abstract
Polyphenols are representative bioactive substances with diverse biological effects. Here, we show that apigenin, a flavonoid, has suppressive effects on microRNA (miRNA) function. The effects were mediated by impaired maturation of a subset of miRNAs, probably through inhibition of the phosphorylation of TRBP, a component of miRNA-generating complexes via impaired mitogen-activated protein kinase (MAPK) Erk activation. While glucose intolerance was observed in miRNA103 (miR103)-overexpressing transgenic mice, administration of apigenin improved this pathogenic status likely through suppression of matured miR103 expression levels. These results suggest that apigenin may have favorable effects on the pathogenic status induced by overexpression of miRNA103, whose maturation is mediated by phosphorylated TRBP.
Similar content being viewed by others
Introduction
Polyphenols, common components of many popular drinks and foods and caffeine, an alkaloid in various seeds and leaves, are representative bioactive substances with diverse biological effects1,2. However, while some effects have been examined in detail3, the molecular mechanisms underlining these biological effects are mostly undetermined.
MicroRNAs (miRNAs) are short, single-stranded, non-coding RNAs expressed in most organisms ranging from plants to vertebrates4. Primary miRNAs, which possess stem-loop structures, are processed into mature miRNAs by Drosha, Dicer, RNA polymerase III and other related molecules. These mature miRNAs then bind the RNA-induced silencing complex (RISC) and the resulting co-complex directly binds the 3′-untranslated regions (3′-UTRs) of target mRNAs to act as suppressors of translation and gene expression. Thus, dependent upon the identity of the target mRNAs, miRNAs are responsible for the control of various biological functions, including cell proliferation, apoptosis, differentiation, metabolism, oncogenesis and oncogenic suppression5,6,7,8,9. For example, it was reported recently that expression of miRNA103 and 107 (miR103 and 107) was upregulated in obese mice and that the gain of miR103 function in either liver or fat was sufficient to induce impaired glucose homeostasis10.
Because the effects of bioactive substances are diverse and the functions of miRNAs result in diverse biological consequences, we hypothesized that some effects of bioactive substances may depend on modulation of miRNA function. In this study, we examined whether polyphenols and caffeine affect miRNA function and determined the molecular mechanisms underlying these effects. In addition, we applied the results obtained here to clinically relevant models to facilitate their use in practical applications.
Results
Apigenin suppresses miRNA function
To determine the effects of polyphenols and caffeine on miRNA function, we determined the luciferase activities of several types of reporters constructed containing miRNA-binding sites (the function of which is suppressed by corresponding miRNAs) upon treatment with caffeine or polyphenols. The polyphenols used here were apigenin, procyanidin A2 and procyanidin B2 from flavonoids and chlorogenic acid from phenolic acid. A cell line derived from the liver, Huh7, was used because substances in food theoretically flow into the liver first through the portal vein immediately after intestinal absorption. Among the bioactive substances examined, only apigenin significantly inhibited the effects of miRNAs such as miR122, miR185 and miR103 (Figure 1a), which are highly expressed in the liver11. The effects were similarly observed irrespective of endogenous miRNAs or exogenous overexpression of corresponding miRNAs (Figure 1a and b) in a dose-dependent manner (Figure 1c). Another liver cell line, Hep3B, showed similar results, suggesting that the effects were not cell line-specific (Supplementary Figure 1a, b and c). The effects were detected with 5 μM apigenin; this concentration is physiologically attainable12,13,14. These results suggest that apigenin has suppressive effects on miRNA function.
Apigenin inhibits miRNA maturation from miRNA precursors
To elucidate the molecular mechanisms underlying the inhibitory effects of apigenin on miRNA function, we first determined the expression levels of miRNA pathway-related molecules including Drosha, DGCR8, KSRP, Argonaute 2 (Ago2) and Dicer in the presence of apigenin. While the expression levels of Drosha, Ago2 and Dicer proteins appeared to decrease slightly after a high dose of apigenin, no significant changes were observed in the expression levels of these proteins (Figure 2a and Supplementary Figure 2a). Next, we examined the expression and maturation of miRNAs by quantitative real-time polymerase chain reaction (qRT-PCR) and Northern blotting (Figure 2b and Supplementary Figure 2b). Expression levels of mature endogenous miR122, miR103 and miR185 decreased and accumulation of precursor miRNAs was also observed after apigenin treatment (Figure 2b), suggesting that maturation from miRNA precursors was decreased. In addition, a comprehensive miRNA microarray analysis confirmed that apigenin altered the expression levels of a major subset of miRNAs (Supplementary Figure 2c; the raw data were deposited in the GEO database; GSE46526). However, some miRNAs, such as let-7, were not affected by apigenin treatment, which was confirmed by qRT-PCR (Figure 2b). These results suggest that apigenin has an inhibitory effect on the maturation of a subset of miRNAs.
Apigenin inhibits phosphorylation of TRBP
The microRNA-generating complex is composed of Dicer and phospho-TRBP isoforms15 and TRBP phosphorylation enhances the maturation of a subset of miRNAs through stabilization of the microRNA-generating complexes15. Phosphorylation of TRBP is mediated by mitogen-activated protein kinase (MAPK) Erk15. Because apigenin is known to inhibit Erk activity16,17,18,19, we hypothesized that the inhibitory effects of apigenin on miRNA maturation may be mediated by decreased phosphorylation of TRBP through inhibition of Erk. Consistent with previous reports, although caffeine had no effect on the Erk phosphorylation status, apigenin clearly inhibited Erk phosphorylation 24 h post-treatment without changes in total Erk levels (Figure 3a). Concordantly, SRE-driven reporter activities were diminished by apigenin treatment (Figure 3b), suggesting that apigenin indeed inhibited an Erk-mediated intracellular signaling pathway, consistent with previous reports16,17,18,19. While TRBP was phosphorylated under normal serum culture conditions and its phosphorylation status did not change with caffeine treatment, its phosphorylation was inhibited by apigenin (Figure 3c). This effect was confirmed by electrophoresis in a phos-tag gel, which showed a clear slow-migrating band, indicating that TRBP was phosphorylated in control and caffeine-treated conditions, but its phosphorylation was inhibited upon treatment with apigenin (Figure 3d). To confirm that Erk activity was inhibited by apigenin following TRBP phosphorylation, we examined the effects of apigenin using Huh7 cells stably expressing constitutively active Mek1 (CA-MEK) on TRBP phosphorylation. As shown in Figure 3e, the degree of TRBP phosphorylation was increased only by CA-MEK expression and the augmented phosphorylation was not diminished by apigenin treatment (Figure 3e), suggesting that the effects of apigenin could not be observed under the induced Erk activation. That is, the effects of apigenin were most probably mediated by inhibition of Erk activation. In addition, we established Huh7 cells stably expressing dominant negative Erk (DN-Erk). As predicted, the levels of mature miRNA103, 122 and 185, were decreased in DN-Erk expressing cells, but were slightly increased in CA-MEK expressing cells, irrespective of apigenin treatment (Figure 3f). The expression levels of mature let-7, which were examined as a representative miRNA that was not affected by apigenin treatment in the miRNA microarray (Figure 3f), were not changed by enforced expression of DN-Erk or CA-MEK, suggesting that this miRNA maturation is not significantly regulated by MAPK activity or TRBP phosphorylation, consistent with a previous report15. These results suggest that apigenin inhibits Erk phosphorylation and subsequent decreased MAPK activity leads to a decrease in TRBP phosphorylation, which may result in decreased maturation of a subset of miRNAs.
Apigenin improves glucose tolerance through inhibition of miRNA function
To apply the above results in a clinical setting, we focused on recent findings demonstrating that a gain of miR103/107 expression induces impaired glucose homeostasis in vivo10. To utilize this, we generated transgenic mice expressing a miR103 precursor under control of the CMV promoter (Supplementary Figure 3a). Overexpression of miR103 in these mice was confirmed by Northern blotting against mature miR103 in liver tissues (Figure 4a and Supplementary Figure 3b). No significant over-saturation of RISC complexes due to overexpressing miR103 in these mice was confirmed by a lack of significant changes in the expression levels of other mature miRNAs, such as miR122 and miR185 (Figure 4a). As expected from a previous report10, these miR103 transgenic mice showed an increase in both random and fasting blood-glucose levels and insulin levels (Supplementary Figure 3c and d). The mean size of adipocytes in visceral fat was larger in normal chow fed miR103 transgenic mice than in control mice and their size became larger nearly in parallel in both control and miR103 transgenic mice under a high-fat diet (Supplementary Figure 3e).
To determine the effect of apigenin in these models, 40 mg/kg apigenin was intraperitoneally injected daily for 14 days in miR103 transgenic mice. The level of mature miR103 was decreased and precursors accumulated in apigenin-treated mice, as determined by Northern blotting and qRT-PCR (Figure 4b and Supplementary Figure 4a and b). Similar to the in vitro results, levels of mature miR122 and miR185, but not let-7, in the liver tissues were also decreased by apigenin treatment (Supplementary Figure 4a and b). Phosphorylated TRBP in the liver tissues was decreased in apigenin-treated mice, as determined by a retarded band in the phos-tag gel (Figure 4c), consistent with the in vitro results (Figure 3d). Erk phosphorylation was consistently decreased following apigenin treatment (Supplementary Figure 4c). In addition, we confirmed the upregulated expression level of caveolin-1, a major regulator of the insulin receptor, which is a direct target gene of miR10310 in these tissues (Supplementary Figure 4c). As expected from these results, apigenin-treated miR103 transgenic mice showed decreased random and fasting blood glucose-levels (Figure 4d). While miR103 transgenic mice showed impaired glucose tolerance after an intraperitoneal glucose injection, apigenin treatment significantly suppressed these phenomena (Figure 4e). Similarly, while miR103 transgenic mice showed increased glucose production during an intraperitoneal pyruvate-tolerance test, apigenin treatment also suppressed these effects (Figure 4f). In addition, an increased number of small adipocytes and a decreased number of large adipocytes were observed in apigenin-treated miR103 transgenic mice (Supplementary Figure 3e and f). These results suggest that apigenin may have beneficial effects on pathological conditions in miR103 transgenic mice.
Discussion
In this study, we demonstrated that apigenin (4′,5,7-trihydroxyflavone) has inhibitory effects on the maturation processes of a subset of miRNAs and subsequent miRNA function. These effects may be mediated through inhibition of TRBP phosphorylation, possibly through inhibition of Erk activation. These results suggest that apigenin may be utilized to improve miRNA-mediated pathogenic states, such as glucose tolerance, induced by the over-expression of miRNA103.
Bioactive substances, such as caffeine and polyphenols, have been reported to have pleiotropic physiological effects3,20. However, those phenomena are descriptive in most cases and the underlying mechanisms are largely unclear. Apigenin, which is present in many fruits and vegetables, also has diverse biological effects, including improvement of the cancer cell response to chemotherapy21, tumorigenesis13,22, modulating immune cell function23 and anti-platelet activity24. In this study, we showed that apigenin inhibits TRBP phosphorylation and its related miRNA maturation through inhibition of MAPK Erk activation. This modulation of miRNA function by apigenin may account, at least in part, for its various reported biological effects.
Phosphorylation of TRBP is mediated by Erk15. We showed clear inhibition of Erk phosphorylation by apigenin. Although previous studies have reported the inhibition of Erk activation by apigenin16,17,18,19, the underlying mechanisms were unknown. Because Erk has many biological functions in intracellular signaling, modulation of TRBP phosphorylation and miRNA expression induced by Erk inhibition through apigenin is likely a part of the phenotype. To clarify the biological function of apigenin, identification of molecules on which apigenin directly acts must be the next step.
Another important finding in this study was the impaired glucose tolerance observed in miR103 transgenic mice. Previous studies showed that recombinant adenoviruses expressing the miR103/107 family (only one nucleotide difference in miR103 and miR107 at position 21) and a gain of miR103/107 function by transient infection in mice was sufficient to induce impaired glucose homeostasis and these miRNAs play a central role in insulin sensitivity10. In this study, we confirmed that constitutive expression of miR103 in mice resulted in impaired glucose tolerance and increased size of adipocytes. These mice may represent a new in vivo model of metabolic disorders and facilitate development of new drugs targeting impaired glucose tolerance. In fact, we found that apigenin reversed impaired glucose tolerance in miR103-transgenic mice. Because apigenin is one of the flavonoids and is present in high content in celery and parsley, intake of apigenin from foods or dietary supplements may have some favorable effects on glucose intolerance induced by overexpression of miRNA levels, even if it does not completely overcome impaired glucose tolerance.
Phosphorylated TRBP is not related to the maturation of all miRNAs, but rather a subset of miRNAs15. With this respect, apigenin may have favorable effects on the pathogenic status induced by overexpression or overfunction of the miRNAs to which phosphorylated TRBP is related. Maturation of miR122, a liver-specific miRNA, is at least partly regulated by apigenin, as shown in our study, its crucial function in cholesterol synthesis11,25,26,27,28 and hepatitis c viral replication29,30. Therefore, apigenin may also have beneficial effects on these conditions. Other effects of apigenin on the pathological state may be necessary to reconsider from the point of view of overexpression or overfunction of specific miRNAs.
Simultaneously, one should be cautious about the modulation of miRNA function by apigenin. Because some miRNAs may have favorable effects on human health, apigenin might be harmful if it inhibits the maturation and function of such miRNAs. For example, inhibitory effects on tumor-suppressive miRNAs should be avoided. Caution regarding these issues is necessary and, in parallel, the biological functions of miRNAs in general should be further examined.
In summary, we showed that apigenin displays inhibitory effects on the phosphorylation of TRBP and its subsequent miRNA maturation and function through regulation of Erk activity. Decreasing miRNA function may be used for treatment of conditions induced by over-functioning of miRNAs. Moreover, clarifying the as-yet-undiscovered functions of bioactive substances is important. Similar strategies to those used here may also be applied to other bioactive substances whose effects have been reported but the mechanisms are as yet undetermined.
Methods
Cell culture
The human hepatocellular carcinoma cell lines, Huh7 and Hep3B, were obtained from the Japanese Collection of Research Bioresources (JCRB, Osaka, Japan). All cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum.
Reagents
Caffeine, apigenin and chlorogenic acid were purchased from Wako Chemicals (Osaka, Japan). Procyanidin A2 and B2 were purchased from Indofine Chemical (Hillsborough, NJ) and ChromaDex (Irvine, CA). Caffeine, chlorogenic acid and procyanidin B2 were dissolved in water. Apigenin and procyanidin A2 were dissolved in dimethyl sulfoxide (DMSO). Caffeine, chlorogenic acid and procyanidin A2 and B2 were added at concentrations of 20 μM, 10 μM, 50 μg/mL and 50 μg/mL, respectively, as reported previously31,32,33,34. Apigenin was used at 10 μM unless otherwise specified for in vitro studies and 40 mg/kg was used for intraperitoneal injection daily for in vivo studies. An equal volume of DMSO only was used as a negative control.
Mouse experiments
Experimental protocols were approved by the Ethics Committee for Animal Experimentation at the Graduate School of Medicine, the University of Tokyo and the Institute for Adult Disease, Asahi Life Foundation, Japan and conducted in accordance with the Guidelines for the Care and Use of Laboratory Animals of the Department of Medicine, the University of Tokyo and the Institute for Adult Disease, Asahi Life Foundation.
Plasmids, transfection and dual luciferase assays
Plasmids expressing miR122 and miR185 precursors and the corresponding firefly luciferase-based reporters have been described previously8,35. Plasmids expressing miRNA-103 precursors and the corresponding luciferase reporter were newly constructed according to protocols reported previously8. To determine MAPK pathway activity, SRE-driven luciferase was transfected and dual luciferase assays were performed as described previously9, with the exception that pGL4.74, a control plasmid containing Renilla reniformis (sea pansy) luciferase under control of the herpes simplex virus thymidine kinase promoter (Promega), was used as an internal control. Chemicals were added at 24 h and the reporter assays were done 48 h post-transfection. Constitutively active MEK1(DD) and dominant negative Erk(K/N) constructs with zeocin resistance genes were kindly provided by Prof. Takekawa (The Institute of Medical Sciences, the University of Tokyo)36. After transfection, the cells were selected with 6 μg/mL zeocin to establish cells stably expressing those constructs.
Western blot analysis
Protein lysates were prepared from cells or mouse liver tissues for immunoblotting analyses. Western blotting was performed as described previously8. Primary antibodies were purchased from Sigma (DGCR8, #SAB4200088; Dicer, #SAB4200087; TRBP2, #SAB4200111; β-actin, #A5441), Bethyl (KSRP, A302-021), Wako (Ago2, 015-22031) and Cell Signaling (Drosha, #D28B1; Phospho-Erk, #9101; Total Erk, #4695; myc-tag, #2276; Caveolin, #3267).
Northern blotting of miRNAs
Northern blotting of miRNAs was performed as described previously9. Briefly, total RNA was extracted using TRIzol Reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. Ten micrograms of RNA were resolved in denaturing 15% polyacrylamide gels containing 7 M urea in 1× TBE and then transferred to a Hybond N+ membrane (GE Healthcare) in 0.25× TBE. Membranes were UV-crosslinked and prehybridized in hybridization buffer. Hybridization was performed overnight at 42°C in ULTRAhyb-Oligo Buffer (Ambion) containing a biotinylated probe specific for miR122 (CAA ACA CCA TTG TCA CAC TCC A), miR103 (TCA TAG CCC TGT ACA ATG CTG CT), miR185 (TCA GGA ACT GCC TTT CTC TCC A) and let-7g (AAC TGT ACA AAC TAC TAC CTC A), which had been heated to 95°C for 2 min. Membranes were washed at 42°C in 2× SSC containing 0.1% SDS and the bound probe was visualized using a BrightStar BioDetect Kit (Ambion). Blots were stripped by boiling in a solution containing 0.1% SDS and 5 mM EDTA for 10 min prior to rehybridization with a U6 probe (CAC GAA TTT GCG TGT CAT CCT T).
Quantitative RT-PCR analysis of miRNA expression
To determine miR122, miR103, miR185 and let-7g expression levels, cDNA was first synthesized from RNA and quantitative PCR was then performed using Mir-X miRNA First-Strand Synthesis and SYBR qRT-PCR Kit (Clontech). The expression levels of miRNA precursor were determined according to the previous report37 using the reported primers. Relative expression values were calculated by the CT-based calibrated standard curve method. These calculated values were then normalized to the expression of U6 snRNA. The reverse primer was provided in the kit.
Determining TRBP phosphorylation status
Plasmids expressing wild-type TRBP and kinase-dead TRBP (TRBP SΔA) were kindly provided by Professor Liu15. Twenty-four hours after transfection into Huh7 cells with corresponding plasmids, substances were treated for 24 h and cell lysates were collected for subsequent Western blotting. To better discriminate the phosphorylated form of TRBP from the unphosphorylated form, a Mn2+-Phos-tag SDS-PAGE gel (Wako) was used according to the manufacturer's instructions.
Generation of miR103-expressing transgenic mice
To construct transgenic mice, plasmids expressing miRNA-103 precursors were modified as follows: to add the SV40 poly(A) tail signal downstream of the miR103 precursor sequences, the pCDH-miR103 precursor-expressing plasmid was digested at the NotI restriction site and PCR-amplified poly(A) tail signal sequences were digested with ClaI from the original plasmid as a template was inserted by the Infusion cloning system (Clontech, Mountain View, CA). A DNA fragment of 1,125 bp, containing the CMV promoter region, the 470-bp genomic region for the miR103 precursor and a SV40 poly(A) tail signal, was resected from the constructed plasmid by digestion with ClaI. Stable C57BL/6 embryonic stem (ES) cell lines were generated by electroporation of the linearized transgene and the resulting cells were injected into blastocysts by the UNITECH Company (Chiba, Japan). Genotyping was performed by PCR using DNA isolated from tail snips. Four different mouse lines were maintained and the male littermates were used in the experiments.
Glucose test
Blood glucose was tested using a Glucose Pilot system (Iwai Chemical, Japan). Glucose tolerance and pyruvate tolerance tests were performed by intraperitoneal injection of glucose (2 g/kg) or pyruvate (2 g/kg) after fasting overnight. Blood glucose levels were measured before injection (0 min) and at 15, 30, 60 and 120 min after injection.
Adipocyte size
Visceral fat tissues stained with hematoxylin and eosin were analyzed using the Image-J software. One hundred adipocytes were measured per animal to determine adipocyte size. The high-fat diet was purchased from CLEA-Japan (Tokyo, Japan).
miRNA microarray analyses
miRNA microarray analysis was performed using miRNA oligo chips (Toray Industries, Tokyo, Japan). Normalization was performed using the intensities from U6, instead of the standard global normalization. The data and the protocols were deposited in a public database (Please refer the following link during the review process; http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=frwpxomkicoicte&acc=GSE46526).
Statistical analysis
Statistically significant differences between groups were determined using Student's t-test when variances were equal. When variances were unequal, Welch's t-test was used. P-values less than 0.05 were considered to indicate statistical significance.
References
Surh, Y. J. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 3, 768–780 (2003).
D'Incalci, M., Steward, W. P. & Gescher, A. J. Use of cancer chemopreventive phytochemicals as antineoplastic agents. Lancet Oncol 6, 899–904 (2005).
Baur, J. A. et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444, 337–342 (2006).
Carrington, J. & Ambros, V. Role of microRNAs in plant and animal development. Science 301, 336–338 (2003).
Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism and function. Cell 116, 281–297 (2004).
Ambros, V. The functions of animal microRNAs. Nature 431, 350–355 (2004).
Lu, J. et al. MicroRNA expression profiles classify human cancers. Nature 435, 834–838 (2005).
Kojima, K. et al. MicroRNA122 is a key regulator of α-fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma. Nat Commun 2, 338 (2011).
Takata, A. et al. MicroRNA-140 acts as a liver tumor suppressor by controlling NF-κB activity by directly targeting DNA methyltransferase 1 (Dnmt1) expression. Hepatology 57, 162–170 (2013).
Trajkovski, M. et al. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature 474, 649–653 (2011).
Krützfeldt, J. et al. Silencing of microRNAs in vivo with ‘antagomirs’. Nature 438, 685–689 (2005).
Budhraja, A. et al. Apigenin induces apoptosis in human leukemia cells and exhibits anti-leukemic activity in vivo. Mol Cancer Ther 11, 132–142 (2012).
Shukla, S. et al. Blockade of beta-catenin signaling by plant flavonoid apigenin suppresses prostate carcinogenesis in TRAMP mice. Cancer Res 67, 6925–6935 (2007).
Wang, W. et al. Cell-cycle arrest at G2/M and growth inhibition by apigenin in human colon carcinoma cell lines. Mol Carcinog 28, 102–110 (2000).
Paroo, Z., Ye, X., Chen, S. & Liu, Q. Phosphorylation of the human microRNA-generating complex mediates MAPK/Erk signaling. Cell 139, 112–122 (2009).
Yi Lau, G. T. & Leung, L. K. The dietary flavonoid apigenin blocks phorbol 12-myristate 13-acetate-induced COX-2 transcriptional activity in breast cell lines. Food Chem Toxicol 48, 3022–3027 (2010).
Tatsuta, A. et al. Suppression by apigenin of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in Wistar rats. Clin Exp Metastasis 18, 657–662 (2000).
Yin, F., Giuliano, A. E. & Van Herle, A. J. Signal pathways involved in apigenin inhibition of growth and induction of apoptosis of human anaplastic thyroid cancer cells (ARO). Anticancer Res 19, 4297–4303 (1999).
Kuo, M. L. & Yang, N. C. Reversion of v-H-ras-transformed NIH 3T3 cells by apigenin through inhibiting mitogen activated protein kinase and its downstream oncogenes. Biochem Biophys Res Commun 212, 767–775 (1995).
Yao, S. L. et al. Selective radiosensitization of p53-deficient cells by caffeine-mediated activation of p34cdc2 kinase. Nat Med 2, 1140–1143 (1996).
Chan, L. P. et al. Apigenin induces apoptosis via tumor necrosis factor receptor- and Bcl-2-mediated pathway and enhances susceptibility of head and neck squamous cell carcinoma to 5-fluorouracil and cisplatin. Biochim Biophys Acta 1820, 1081–1091 (2012).
Mafuvadze, B., Liang, Y., Besch-Williford, C., Zhang, X. & Hyder, S. M. Apigenin induces apoptosis and blocks growth of medroxyprogesterone acetate-dependent BT-474 xenograft tumors. Horm Cancer 3, 160–171 (2012).
Nicholas, C. et al. Apigenin blocks lipopolysaccharide-induced lethality in vivo and proinflammatory cytokines expression by inactivating NF-kappaB through the suppression of p65 phosphorylation. J Immunol 179, 7121–7127 (2007).
Landolfi, R., Mower, R. L. & Steiner, M. Modification of platelet function and arachidonic acid metabolism by bioflavonoids. Structure-activity relations. Biochem Pharmacol 33, 1525–1530 (1984).
Hsu, S. H. et al. Essential metabolic, anti-inflammatory and anti-tumorigenic functions of miR-122 in liver. J Clin Invest 122, 2871–2883 (2012).
Lanford, R. E. et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327, 198–201 (2010).
Elmén, J. et al. LNA-mediated microRNA silencing in non-human primates. Nature 452, 896–899 (2008).
Esau, C. et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 3, 87–98 (2006).
Jopling, C. L., Yi, M., Lancaster, A. M., Lemon, S. M. & Sarnow, P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 309, 1577–1581 (2005).
Lindow, M. & Kauppinen, S. Discovering the first microRNA-targeted drug. J Cell Biol 199, 407–412 (2012).
Ku, B. M. et al. Caffeine inhibits cell proliferation and regulates PKA/GSK3β pathways in U87MG human glioma cells. Mol Cells 31, 275–279 (2011).
Nishizuka, T. et al. Procya nidins are potent inhibitors of LOX-1: a new player in the French Paradox. Proc Jpn Acad Ser B Phys Biol Sci 87, 104–113 (2011).
Teraoka, M. et al. Cytoprotective effect of chlorogenic acid against α-synuclein-related toxicity in catecholaminergic PC12 cells. J Clin Biochem Nutr 51, 122–127 (2012).
Shukla, S. & Gupta, S. Apigenin: a promising molecule for cancer prevention. Pharm Res 27, 962–978 (2010).
Takata, A. et al. MicroRNA-22 and microRNA-140 suppress NF-κB activity by regulating the expression of NF-κB coactivators. Biochem Biophys Res Commun 411, 826–831 (2011).
Kubota, Y., O'Grady, P., Saito, H. & Takekawa, M. Oncogenic Ras abrogates MEK SUMOylation that suppresses the ERK pathway and cell transformation. Nat Cell Biol 13, 282–291 (2011).
Suzuki, H. I. et al. Modulat ion of microRNA processing by p53. Nature 460, 529–533 (2009).
Acknowledgements
This work was supported by Grants-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology, Japan (#25293076 and #24390183) (to M. Otsuka and K. Koike), by Health Sciences Research Grants of The Ministry of Health, Labor and Welfare of Japan (to K. Koike) and grants from the Nestlé Nutrition Council, Japan (to A.T.) and the Foundation of All Japan Coffee Association (to M. Otsuka).
Author information
Authors and Affiliations
Contributions
M.Ohno, C.S. and M.Otsuka planned the research and wrote the paper. M.Ohno, C.S., T.K., T.Y., A.T., K.Kojima and M.Otsuka performed the majority of the experiments. M.A. and H.Y. contributed materials. Y.K. supported several experiments. K.Koike supervised the entire project.
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Electronic supplementary material
Supplementary Information
Supplementary Information
Rights and permissions
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/
About this article
Cite this article
Ohno, M., Shibata, C., Kishikawa, T. et al. The flavonoid apigenin improves glucose tolerance through inhibition of microRNA maturation in miRNA103 transgenic mice. Sci Rep 3, 2553 (2013). https://doi.org/10.1038/srep02553
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/srep02553
This article is cited by
-
Circulating miRNA profiles in mice plasma following flavonoid intake
Molecular Biology Reports (2022)
-
Hyssopus officinalis exerts hypoglycemic effects on streptozotocin-induced diabetic rats via modulating GSK-3β, C-fos, NF-κB, ABCA1 and ABGA1 gene expression
Journal of Diabetes & Metabolic Disorders (2020)
-
Diabetes, microRNA, and Nutrition in Geriatrics
Current Geriatrics Reports (2020)
-
Role of non-coding RNAs in liver disease progression to hepatocellular carcinoma
Archives of Pharmacal Research (2019)
-
Plant-derived antivirals against hepatitis c virus infection
Virology Journal (2018)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.